• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Lansoprazole Teva
    / Teva

    Active Ingredient
    Lansoprazole 15 mg, 30 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    30 x 15 mg

    partial basket chart 84717 12430


    30 x 30 mg

    partial basket chart 84718 12431

    Related information


    See prescribing information for full details.


    Treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis and acid related disorders of the upper GI tract. Healing, long term treatment and maintenance therapy for patients with gastro esophageal reflux disease (GERD) or duodenal ulcer. Prevention of relapse in patients with GERD or duodenal ulcer. Eradication of H. pylori from the upper GI tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). Short term, treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. Long-term management of pathological hypersecretory conditions including Zollinger Ellison syndrome. Treatment and prophylaxis of NSAID- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued NSAID treatment.


    Hypersensitivity to any ingredient of the preparation. Pregnancy.

    Special Precautions

    Please contact distributing company for full details.

    Side Effects

    Please contact distributing company for full details.

    Drug interactions

    Please contact distributing company for full details.

    Teva Pharmaceutical Industries Ltd, Israel